BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

...tool compound decreased proteinuria, clinical disease scores, renal T cell infiltration, spleen size, autoantibody titers, immune complex...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...immune-related diseases associated with the alternative pathway of the complement system, including C3 glomerulopathy (C3G) immune complex...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...immune-related diseases associated with the alternative pathway of the complement system, including C3 glomerulopathy (C3G) immune complex...
BioCentury | Aug 29, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
BioCentury | Aug 29, 2018
Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
BioCentury | Mar 2, 2018
Company News

MedImmune spins out autoimmune play Viela

...autoimmune receptor, and is expected to begin a Phase I trial this year to treat immune complex-driven...
BioCentury | Feb 28, 2018
Company News

MedImmune spins out autoimmune play Viela

...autoimmune receptor, and is expected to begin a Phase I trial this year to treat immune complex-driven...
BioCentury | Feb 26, 2018
Company News

Achillion rises on positive opinion for C3G therapy

...which has Orphan Drug designation in the U.S., is also in Phase II testing for immune complex-mediated...
Items per page:
1 - 10 of 77
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

...tool compound decreased proteinuria, clinical disease scores, renal T cell infiltration, spleen size, autoantibody titers, immune complex...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...immune-related diseases associated with the alternative pathway of the complement system, including C3 glomerulopathy (C3G) immune complex...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...immune-related diseases associated with the alternative pathway of the complement system, including C3 glomerulopathy (C3G) immune complex...
BioCentury | Aug 29, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
BioCentury | Aug 29, 2018
Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
BioCentury | Mar 2, 2018
Company News

MedImmune spins out autoimmune play Viela

...autoimmune receptor, and is expected to begin a Phase I trial this year to treat immune complex-driven...
BioCentury | Feb 28, 2018
Company News

MedImmune spins out autoimmune play Viela

...autoimmune receptor, and is expected to begin a Phase I trial this year to treat immune complex-driven...
BioCentury | Feb 26, 2018
Company News

Achillion rises on positive opinion for C3G therapy

...which has Orphan Drug designation in the U.S., is also in Phase II testing for immune complex-mediated...
Items per page:
1 - 10 of 77